ArticleMedscape journal of medicine2008
Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005.
Article in Medscape journal of medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies.Influenza and other respiratory viruses · 2013Pooled it
- Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic.Influenza and other respiratory viruses · 2013Pooled it
- Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).The Cochrane database of systematic reviews · 2012Pooled it
- Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies.Annals of internal medicine · 2012Pooled it
- Development and validation of a nomogram to predict severe influenza.Immunity, inflammation and disease · 2024Article
- The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
- AMMI Canada 2023 update on influenza: Management and emerging issues.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2023Article
- Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir.Medicina (Kaunas, Lithuania) · 2023Article
- Antiviral Use and Health Care Use Among US Patients With Rheumatoid Arthritis and Influenza in Three Influenza Seasons, 2016-2019.ACR open rheumatology · 2022Article
- Factors Affecting the Incidence of Hospitalized Pneumonia after Influenza Infection in Korea Using the National Health Insurance Research Database, 2014-2018: Focusing on the Effect of Antiviral Therapy in the 2017 Flu Season.Journal of Korean medical science · 2020Article
- Oseltamivir use amongst hospitalized patients infected with influenza.Influenza and other respiratory viruses · 2014Article
- Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.Advances in therapy · 2011Review
- Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States.Emerging infectious diseases · 2011Article
- Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.The Journal of antimicrobial chemotherapy · 2010Review
- Use of oseltamivir in children.Canadian family physician Medecin de famille canadien · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextInfluenza results in large numbers of secondary complications and hospitalizations.
objectiveTo assess the impact of oseltamivir on influenza-related complications and hospitalizations by analyzing health insurance claims data for 6 influenza seasons.
designA retrospective cohort study utilizing claims data from the 2000-2005 influenza seasons.
settingClaims data were obtained from Thomson Healthcare MarketScan Research Databases. PATIENTS: Patients prescribed oseltamivir within 1 day of influenza diagnosis were compared to those prescribed no antiviral therapy (controls). OUTCOMES: Frequencies of pneumonia, other respiratory illnesses, and otitis media, and rates of hospitalization, were compared for the oseltamivir and no antiviral groups. Expenditure was also analyzed. Relative risk (RR) for each outcome was assessed using Cox proportional hazards regression.
resultsOverall, 31,674 patients received oseltamivir and were propensity matched to patients with no antiviral prescription. Oseltamivir reduced the risk of diagnosis of pneumonia by 15% (RR 0.85, 95% confidence interval [CI] 0.73, 0.98), other respiratory illnesses by 20% (RR 0.80, 95% CI: 0.76, 0.83), and otitis media and its complications by 31% (RR 0.69, 95% CI: 0.61, 0.79). The greatest reductions in pneumonia risk, of 57% and 52%, were observed for children aged 6-12 years (RR 0.43, 95% CI: 0.26, 0.71) and 1-2 years (RR 0.48, 95% CI: 0.24, 0.99), respectively. Overall, hospitalization rates were reduced by 38% (RR 0.62, 95% CI: 0.52, 0.74) in the oseltamivir group compared with the no antiviral group. Total adjusted expenditures in the oseltamivir and no antiviral groups were not significantly different.
conclusionsOseltamivir reduced the relative risk of influenza-related complications and hospitalization when prescribed immediately upon presentation of influenza.
Indexed as
Identifiers
18679536PMC2491667W1502852025What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.